Wegovy 0.25mg effectiveness: what to expect from the first four weeks

Step 1: Why Wegovy begins at a dose too low to drive weight loss

Semaglutide works by activating GLP-1 receptors in the gut and brain, slowing gastric emptying and reducing appetite. At 0.25mg that effect is present but modest. The prescribing schedule (verified in the Wegovy SmPC on the electronic Medicines Compendium) starts here deliberately: a lower concentration gives the gut time to adjust before the dose climbs.

Think of it less as week one of treatment and more as week one of preparation. The people who tolerate the later, higher doses best are usually those who took the titration seriously rather than rushing it. Your prescriber controls the pace; the schedule is not something to hurry along at home.

Nausea, mild indigestion and loose stools are the side effects most commonly reported at this stage, as the NHS semaglutide medicines page outlines. They tend to be at their most noticeable in the first few days after each new dose, then settle. Eating smaller meals, staying well hydrated and avoiding rich or fatty food helps most people through the adjustment.

One thing worth knowing: the 0.25mg pen and the higher-dose pens in the Wegovy range look similar. Always check the label before injecting, and store the pen in the fridge between 2°C and 8°C, refer to the Patient Information Leaflet for the exact room-temperature window if you ever need to travel with it.

Step 2: What the dose ladder looks like from here

After four weeks at 0.25mg, the prescriber typically moves to 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg, each step separated by around a month. The full picture of the titration is covered in detail on Wegovy's dose schedule if you want to map out the whole timeline.

A question our prescribers hear most weeks is whether someone can skip a dose step if they feel fine. The answer, consistently, is no, the steps exist to protect you from a sudden spike in side effects, not just to manage the ones you notice at the lower dose. The gut adapts progressively; jumping from 0.25mg to 1.0mg in one go significantly increases the chance of vomiting and dehydration.

This is also the stage where people sometimes worry that the medicine is not working. If you find yourself questioning whether 0.25mg semaglutide is doing anything at all, it helps to understand that modest appetite reduction is already underway at 0.5mg and 1.0mg for many people, and measurable weight loss typically follows. The 0.5mg dose and what it delivers is addressed separately for anyone already at that stage. Effectiveness builds with dose; judging the whole course by the first four weeks is like judging a marathon by the first kilometre.

If side effects at any point feel unmanageable (severe vomiting, signs of dehydration, or any symptom you are unsure about) contact your prescriber or a clinician rather than stopping the medicine yourself.

Step 3: When meaningful weight loss typically begins

Published trial data gives the clearest picture. The STEP 1 study, published in the New England Journal of Medicine, followed adults on semaglutide 2.4mg for 68 weeks and found average body-weight reductions of around 15%, a result reached at the maintenance dose after the full titration, not at 0.25mg. That context matters: the clinical evidence for Wegovy's effectiveness is built on the complete course of treatment, used alongside a reduced-calorie diet and increased physical activity.

Most people begin to notice a clearer reduction in hunger somewhere between the 1.0mg and 1.7mg steps. Measurable weight loss on the scales often follows a few weeks after that. Individual responses vary, and a range of factors (starting weight, diet, activity, adherence to the titration) all influence pace. A broader look at which Wegovy dose drives the most meaningful results puts the individual steps in context.

It is worth being honest about what 0.25mg effectiveness actually means: this dose is effective at doing its specific job, which is tolerability. The weight-management results that made Wegovy a licensed treatment in the UK are achieved over months, not weeks, and they depend on reaching and staying at the maintenance dose with your prescriber's guidance. The full Wegovy overview covers the licensed indication, eligibility and what private treatment involves.

A note on eligibility and getting started

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above where a weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea is present. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine approval; a prescriber looks at your full medical picture, including any medicines you already take and any conditions that would affect safety.

For people asking about costs alongside starting treatment, the Wegovy private prescription page sets out what a legitimate, clinically supervised course involves, including what is typically included in a provider's price. Wegovy is a prescription-only medicine; the starting dose, like every subsequent step, requires a clinical assessment.

If you are weighing up whether this is the right treatment for you, the weight-loss treatment overview covers both Wegovy and tirzepatide (Mounjaro) side by side. The MHRA's Yellow Card scheme is the right place to report any side effects you experience once on treatment.